



accessed 5 March 2026).

2.

Mwapasa V, Asante KP, Milligan P, Akech S, Oduro A et al. Impact of introducing the RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster randomised implementation programme. *Lancet*. 2026;407(10541):1796–1808. doi:10.1016/S0140-6736(26)00248-5.

3.

Welaga P, Gyan T, Koram K et al. The Malaria Vaccine Implementation Programme study area in Ghana: results of a household survey prior to the introduction of the RTS,S/AS01 vaccine. *Malar J*. 2026;25:69. doi:10.1186/s12936-025-05778-9.

4.

Walldorf JA, Mayers GF, Amponsa-Achiano K, Jalang'o R, Chisema M et al. Post-introduction evaluation (PIE) of the malaria vaccine introduced in three pilot countries (Ghana, Kenya, and Malawi) in 2021. *Malar J*. 2025;24:354. doi:10.1186/s12936-025-05590-5.

5.

Price J, Collymore Y, Bawa JT, Mkisi RE, Buell C et al. Recommendations to mitigate barriers to uptake and delivery of a four-dose malaria vaccine schedule: insights from the MVIP's qualitative evidence. *Malar J*. 2025;24:408. doi:10.1186/s12936-025-05611-3.

6.

Jalang'o R, Amponsa-Achiano K, Chisema M, Malm K, Khalayi L et al. Subnational introduction of the RTS,S/AS01E malaria vaccine into routine immunization: experience and lessons from the three pilot countries. *Malar J*. 2025;24:244. doi:10.1186/s12936-025-05484-6.

7.

Bushi G, Khatib MN, Renuka Jyothi S, Kaur I, Sharma A et al. Determinants of malaria vaccine acceptance: a systematic review and meta-analysis of awareness, acceptance, hesitancy, and willingness to pay. *Immun Inflamm Dis*. 2025;13(5):e70205. doi:10.1002/iid3.70205.

8.

Meñaca A, Tagbor H, Adjei R, Bart-Plange C, Collymore Y et al. Factors likely to affect community acceptance of a malaria vaccine in two districts of Ghana: a qualitative study. *PLoS One*. 2014;9(10):e109707. doi:10.1371/journal.pone.0109707.

9.

Febir LG, Asante KP, Dzorgbo D-BS, Senah KA, Letsa TS et al. Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. *Malar J*. 2013;12:156. doi:10.1186/1475-2875-12-156.

10.

Price J, Gurley N, Gyapong M, Ansah EK, Awusabo-Asare K et al. Acceptance of and adherence to a four-dose RTS,S/AS01 schedule: findings from a longitudinal qualitative evaluation study for the malaria vaccine implementation programme. *Vaccines*. 2023;11(12):1801. doi:10.3390/vaccines11121801.

11.

Diawara H, Grant J, Dicko A, Traore S, Issiaka D et al. Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context. *BMJ Glob Health*. 2025;10(2):e015524. doi:10.1136/bmjgh-2024-015524.

12.

Abubakar A, Mohammed S, Sadiq A et al. Awareness and acceptability of malaria vaccine among caregivers of under-5 children in Northern Nigeria. *Malar J*. 2023;22:368. doi:10.1186/s12936-023-04768-z.